Feel the Force
–Master Yoda
With this editorial message, I would like to encourage as many of our global interdisciplinary
readers of ∼10,000—and moreover, PubMed readers—to pull the referenced articles below,
and after privately reading them, discuss them in your journal clubs, grand rounds,
and scientific meetings. The implications of the readings relate to how we conduct
our evidence evaluations as presented in published medical literature. Without wanting
to sound overly dramatic, I do believe that we may have witnessed with these publications
a cataclysmic change in the way prospective clinical science and trials in general—specifically,
in spine—will be conducted and reported in the future.
The topic of bone morphogenic protein has surely been a most contentious subject.
Questions of patient safety (cancer risk, heterotopic bone formation, neuritis, dysphagia,
and others) have been raised and the actual likelihood of these possible complications
have been previously discussed here in EBSJ
[1] and in many other publications. It is not an exaggeration to speak of a “war” waged
in the arena of academic publications and the court of public opinions through public
media. To form your own opinion, I ask you to study the articles of Simmonds et al,[2] and Fu et al,[3] which are closely related to the much-anticipated results of the Yale University
Open Data Access study (YODA)[4] published in the June issue of the Annals of Medicine.
The gist of my editorial message is, however, not focused on the merits of bone morphogenic
protein, but rather on the bigger picture of how to conduct large-scale clinical research
going forward. One of the main conclusions of the authors and commentators was that
open data reporting for major clinical trials would have been preferable to avoid
concerns about selective reporting of potentially important clinical findings.[5]
[6] As shown by the open publication of this data in full cooperation with its industrial
sponsor (Medtronic, Inc., Minneapolis, United States), the YODA publications[2]
[3] resulted in a general call to conduct all future clinical trials with full data
transparency and opportunity for data sharing among qualified investigators. This
would signal a major departure from the traditional proprietary- and secrecy-cloaked
nature, not only of industry-sponsored research, but also any form of funded, clinical
trials-type research, while also requiring a review of applicable patient privacy
laws, as some patient identifiers will invariably become more apparent.
However we look at it, the forces YODA has unleashed may be truly transformational;
it will be interesting to see how in the future, possibly contentious device-, technique-,
or medication-based trials will be structured in light of this very noteworthy publication
series. As always, I welcome your opinions in this interesting turn of events in the
field of evidence-based medicine.
